Mablink Bioscience
FranceWho owns Mablink Bioscience?
Mablink Bioscience is a French Biotech company, now owned by Eli Lilly, which acquired it in 2024 from Lazard Elaia Capital.
Hand-verified · updated 2026-04-21
Open JSON · CC-BY
Key facts
- ·Fully exited in 2024 to Eli Lilly.
- ·Average hold across 5 realized cycles: 2 years.
- ·5 distinct PE sponsors across ownership cycles.
Ownership history
5 ownership periods · co-invest detected
ANGELOR sold Mablink Bioscience to Eli Lilly in 2023 after 4 years.
Elaia Partners sold Mablink Bioscience to Eli Lilly in 2023 after 2 years.
Lazard Elaia Capital sold Mablink Bioscience to Eli Lilly in 2024 after 3 years.
Sofinnova Partners sold Mablink Bioscience to Eli Lilly in 2023 after 1 year.
Merieux Equity Partners sold Mablink Bioscience to Eli Lilly and Company in 2023 after 1 year.
More from Elaia Legacy Fund
Other portfolio companies in the same fund.
UKMore PE-backed in Biotech
Comparable biotech deals from other GPs.
USQuestions
Who owns Mablink Bioscience?
Mablink Bioscience is now owned by Eli Lilly, which acquired it in 2024 from Lazard Elaia Capital.
When did Eli Lilly acquire Mablink Bioscience?
Eli Lilly acquired Mablink Bioscience in 2024, buying from Lazard Elaia Capital.
Who did Mablink Bioscience sell to?
Lazard Elaia Capital sold Mablink Bioscience to Eli Lilly in 2024 (Trade Sale). ANGELOR, Elaia Partners and Sofinnova Partners sold Mablink Bioscience to Eli Lilly in 2023 (Trade Sale). Merieux Equity Partners sold Mablink Bioscience to Eli Lilly and Company in 2023 (Trade Sale).
Who has owned Mablink Bioscience over time?
Mablink Bioscience has been through 5 private-equity ownership periods: ANGELOR · via Angelor · 2019–2023 · sold to Eli Lilly · (Trade Sale); Lazard Elaia Capital · via Elaia Legacy Fund · 2021–2024 · sold to Eli Lilly · (Trade Sale); Elaia Partners · via Elaia Alpha II · 2021–2023 · sold to Eli Lilly · (Trade Sale); Merieux Equity Partners · via Mérieux Innovation 1 · 2022–2023 · sold to Eli Lilly and Company · (Trade Sale); Sofinnova Partners · via Sofinnova Capital X · 2022–2023 · sold to Eli Lilly · (Trade Sale).